Arcutis Biotherapeutics
ARQT
103 hedge funds and large institutions have $1.05B invested in Arcutis Biotherapeutics in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 28 increasing their positions, 33 reducing their positions, and 11 closing their positions.
157% more call options, than puts
Call options by funds: $1.3M | Put options by funds: $506K
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
1% more funds holding
Funds holding: 102 → 103 (+1)
0.39% more ownership
Funds ownership: 90.57% → 90.96% (+0.39%)
12% less capital invested
Capital invested by funds: $1.19B → $1.05B (-$140M)
15% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 33
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$25M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$744K |
| 3 |
Millennium Management
New York
|
+$698K |
| 4 |
Blackstone Inc
New York
|
+$551K |
| 5 |
ACM
Altium Capital Management
New York
|
+$540K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$3.05M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$2.85M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.58M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.54M |
ARQT Hedge Fund Activity: Q3 2021 in Review
103 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q3 2021, worth a combined $1.05B — down 12% from $1.19B a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ARQT positions and 11 closed out — a net gain of 1 holder — while 28 added to existing stakes and 33 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $25M. The largest seller was Citadel Advisors, cutting an estimated $4M.
- 103 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q3 2021, up from 102 in Q2 2021.
- Funds reported $1.05B of Arcutis Biotherapeutics stock for Q3 2021, down 12% quarter-over-quarter.
- 12 funds opened new Arcutis Biotherapeutics positions in Q3 2021 and 11 closed out, a net change of +1 holder.
- The largest Arcutis Biotherapeutics buyer in Q3 2021 was Point72 Asset Management, an estimated $25M added.
- The largest Arcutis Biotherapeutics seller in Q3 2021 was Citadel Advisors, an estimated $4M sold.
Based on aggregated 13F filings for Q3 2021.